Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial

NCT07543783 is registered in ClinicalTrials.gov with Third Affiliated Hospital, Sun Yat-Sen University as lead sponsor.

NCT NCT07543783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07543783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial
Lead sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 10, 2026
Completion date
August 31, 2029
Enrollment
38 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

adebrelimab (shr-1316), bevacizumab, hepatocellular carcinoma (hcc)